-
Alfasigma acquires the European license for bentracimab from PhaseBio
prnasia
June 22, 2021
Alfasigma has entered into an exclusive licensing agreement with PhaseBio Pharmaceuticals, Inc., for the commercialization of bentracimab in 49 countries across Europe and other key markets.
-
PhaseBio and BioVectra Enter into Supply Agreement
contractpharma
March 12, 2021
?PhaseBio Pharmaceuticals, a clinical-stage biotech focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra, a global contract development and manufacturing organization (CDMO), have entered a ...
-
PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor
americanpharmaceuticalreview
January 17, 2020
PhaseBio Pharmaceuticals has signed an agreement with Viamet Pharmaceuticals and its wholly-owned subsidiary, Selenity Pharmaceuticals, to acquire all of the assets and intellectual property rights related to certain novel aldosterone synthase inhibitors
-
PhaseBio Announces Completion of Phase 2a Trial of PB2452
americanpharmaceuticalreview
September 26, 2019
PhaseBio Pharmaceuticals announced the completion of its Phase 2a clinical trial of PB2452. Full data from the trial are planned to be presented at an upcoming medical congress.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
